Physician profile
Deepika Arora
NPI 1053689455
$18,075.15
in general payments reported to CMS, 2019-2025
42 companies · $3,579 in 2025
The $3,579 reported for 2025 was more than what 81% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $2,038 · 2021: $2,933 · 2022: $2,705 · 2023: $3,028 · 2024: $2,340 · 2025: $3,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,844 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,843.92 |
| Education | $103.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,338.49 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,859.64 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Janssen Biotech, INC. | $1,368.69 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,117.33 | 2019-2025 | |
| Ucb, INC. | $1,097.09 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $788.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $764.88 | 2019-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $722.24 | 2019-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $719.74 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $644.96 | 2021-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $566.41 | 2021-2025 | Lupkynis |
| Welch Allyn | $520.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $506.48 | 2019-2025 | Strensiq |
| Genzyme Corporation | $342.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $341.94 | 2019-2023 | Orencia |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $309.98 | 2022-2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $181.60 | 2020-2024 | |
| Genentech USA, INC. | $165.94 | 2020-2022 | |
| Organon LLC | $162.78 | 2023-2025 | Hadlima, Renflexis, Nexplanon |
| Fresenius Kabi USA, LLC | $154.18 | 2023-2025 | Idacio |
| Sobi, INC | $152.22 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $124.17 | 2020-2023 | Truxima |
| Hikma Pharmaceuticals USA | $103.64 | 2019-2021 | |
| Octapharma USA, INC. | $97.26 | 2023 | Octagam Immune Globulin (Human) |
| Radius Health, INC. | $90.57 | 2019-2020 | |
| Horizon Therapeutics Plc | $87.03 | 2019-2020 | |
| Almatica Pharma LLC | $85.00 | 2025 | Teriparatide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.45 | 2021-2024 | Cyltezo |
| Tersera Therapeutics LLC | $70.77 | 2024 | Quzyttir |
| Fidia Pharma USA INC. | $67.04 | 2020-2024 | Hymovis |
| Sandoz INC. | $56.77 | 2020-2023 | Hyrimoz |
| Invivyd INC | $56.25 | 2025 | Pemgarda |
| Mallinckrodt Enterprises LLC | $50.78 | 2019 | |
| Novo Nordisk INC | $50.12 | 2022 | |
| Kyowa Kirin, INC. | $44.76 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $42.68 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $41.47 | 2019-2020 | |
| Biocon Biologics INC | $27.85 | 2024 | Hulio |
| Celgene Corporation | $23.38 | 2019 | |
| Mylan Institutional INC. | $20.86 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $15.31 | 2022 | |
| Depuy Synthes Sales INC. | $11.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.